Brief: Mesoblast Posts Ryoncil Q4 Net Revenue Of $36M
10/07/2026 02:14
BRIEF-Mesoblast Posts Ryoncil Q4 Net Revenue Of $36M July 10 (Reuters) - Mesoblast Ltd MSB.AX:
RYONCIL Q4 NET REVENUE OF US$36M AND US$115M FOR FULL YEAR
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil